NASDAQ:NBIX - Neurocrine Biosciences Stock Price, Forecast & News

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) released its earnings results on Tuesday, February, 4th. The company reported $0.35 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.75 by $0.40. The company earned $244.10 million during the quarter, compared to analyst estimates of $231.54 million. Neurocrine Biosciences had a return on equity of 8.27% and a net margin of 4.70%. Neurocrine Biosciences's revenue was up 85.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.19 earnings per share. View Neurocrine Biosciences' Earnings History.

Neurocrine Biosciences is scheduled to release their next quarterly earnings announcement on Monday, May 4th 2020. View Earnings Estimates for Neurocrine Biosciences.

14 equities research analysts have issued 1 year price objectives for Neurocrine Biosciences' stock. Their forecasts range from $88.00 to $153.00. On average, they expect Neurocrine Biosciences' stock price to reach $117.00 in the next year. This suggests a possible upside of 11.7% from the stock's current price. View Analyst Price Targets for Neurocrine Biosciences.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last year. There are currently 4 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neurocrine Biosciences.

Media stories about NBIX stock have trended somewhat negative recently, according to InfoTrie. The research firm ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Neurocrine Biosciences earned a daily sentiment score of -1.6 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Neurocrine Biosciences.

Neurocrine Biosciences saw a decrease in short interest in the month of January. As of January 15th, there was short interest totalling 4,240,000 shares, a decrease of 8.4% from the December 31st total of 4,630,000 shares. Based on an average trading volume of 936,000 shares, the days-to-cover ratio is presently 4.5 days. Currently, 4.7% of the shares of the stock are sold short. View Neurocrine Biosciences' Current Options Chain.

Some companies that are related to Neurocrine Biosciences include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and Repligen (RGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), AbbVie (ABBV), Netflix (NFLX), Gilead Sciences (GILD), Exelixis (EXEL), Twilio (TWLO), Illumina (ILMN) and Sarepta Therapeutics (SRPT).

Neurocrine Biosciences' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Janus Henderson Group PLC (7.99%), Capital International Investors (6.32%), Perceptive Advisors LLC (3.91%), Alliancebernstein L.P. (1.34%), Pictet Asset Management Ltd. (0.93%) and Renaissance Technologies LLC (0.80%). Company insiders that own Neurocrine Biosciences stock include Corinne H Nevinny, Darin Lippoldt, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, Richard F Pops and Stephen A Sherwin. View Institutional Ownership Trends for Neurocrine Biosciences.

NBIX stock was sold by a variety of institutional investors in the last quarter, including Man Group plc, Janus Henderson Group PLC, Perceptive Advisors LLC, Russell Investments Group Ltd., Pictet Asset Management Ltd., Marshall Wace North America L.P., First Trust Advisors LP and Marshall Wace LLP. Company insiders that have sold Neurocrine Biosciences company stock in the last year include Darin Lippoldt, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith and Matt Abernethy. View Insider Buying and Selling for Neurocrine Biosciences.

NBIX stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Sumitomo Mitsui Trust Holdings Inc., Victory Capital Management Inc., Victory Capital Management Inc., Parkman Healthcare Partners LLC, Swiss National Bank, Cubist Systematic Strategies LLC and AXA. View Insider Buying and Selling for Neurocrine Biosciences.

Shares of NBIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NBIX stock can currently be purchased for approximately $104.75.

Neurocrine Biosciences has a market capitalization of $9.67 billion and generates $788.10 million in revenue each year. The company earns $37.01 million in net income (profit) each year or $0.39 on an earnings per share basis. Neurocrine Biosciences employs 585 workers across the globe.View Additional Information About Neurocrine Biosciences.

The official website for Neurocrine Biosciences is http://www.neurocrine.com/.

Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company can be reached via phone at 858-617-7600 or via email at [email protected]